

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)  
180th Meeting of the Vaccines and Related Biological Products Advisory  
Committee  
Silver Spring, MD  
March 7, 2023  
AGENDA**

**Topic:** The Committee will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2023 – 2024 influenza season.

Time	Presentation/Presenter
<b>9:00am – 9:10am</b>	<p><b><u>Opening Remarks: Call to Order and Welcome (5 Min)</u></b></p> <p>Hana El Sahly, M.D. Chair, VRBPAC Professor, Department of Molecular Virology and Microbiology Baylor College of Medicine</p>
<b>9:10am – 9:30am</b>	<p><b><u>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 Min)</u></b></p> <p>Sussan Paydar, Ph.D. Designated Federal Officer, VRBPAC Division Of Scientific Advisors and Consultants, CBER, FDA</p>
<b>9:30am – 9:45am</b>	<p><b><u>Introduction (15 min)</u></b></p> <p><b>Jerry Weir, Ph.D. (10 Min)</b> Director Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA</p> <p>Q &amp; A: 5 min</p>
<b>9:45am – 10:10am</b>	<p><b><u>U.S. Surveillance (25 Min)</u></b></p> <p><b>Lisa Grohskopf, M.D., M.P.H. (20 Min)</b> Medical Officer Epidemiology &amp; Prevention Branch, Influenza Division Centers for Disease Control and Prevention (CDC)</p> <p>Q &amp; A: 5 min</p>

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)  
180th Meeting of the Vaccines and Related Biological Products Advisory  
Committee  
Silver Spring, MD  
March 7, 2023  
AGENDA**

<b>10:10am – 11:20am</b>	<p><b><u>Global Influenza Virus Surveillance and Characterization (70 Min including Q&amp;A)</u></b></p> <p><b>David Wentworth, Ph.D. (60 min)</b> Director, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza Branch Chief, Virology, Surveillance, and Diagnostic Branch Influenza Division Centers for Disease Control and Prevention (CDC)</p> <p>Q &amp; A: 10 min</p>
<b>11:20am – 11:30am</b>	<p><b>Break (10 Min)</b></p>
<b>11:30am – 11:55am</b>	<p><b><u>DoD Influenza Surveillance and Mid-Season Vaccine Effectiveness (25 Min)</u></b></p> <p><b>Anthony Fries, Ph.D. (20 min)</b> DoD Global Respiratory Pathogen Surveillance Program Lead United States Air Force School of Aerospace Medicine</p> <p>Q &amp; A: 5 min</p>
<b>11:55am – 12:20pm</b>	<p><b><u>Candidate Vaccine Strains &amp; Potency Reagents (25 Min)</u></b></p> <p><b>Manju Joshi, Ph.D. (20 Min)</b> Lead Biologist Division of Biological Standards &amp; Quality Office of Compliance and Biologics Quality CBER/FDA</p> <p>Q &amp; A: 5 min</p>
<b>12:20pm – 12:45pm</b>	<p><b><u>Comments from Manufacturer Representative (25 min)</u></b></p> <p><b>Elisabeth Neumeier, D.V.M. (20 Min)</b> Director, Technical Life Cycle Management Influenza Global Vaccines Manufacturing Science and Technology GlaxoSmithKline</p> <p>Q &amp; A: 5 min</p>

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Biologics Evaluation and Research (CBER)  
180th Meeting of the Vaccines and Related Biological Products Advisory  
Committee  
Silver Spring, MD  
March 7, 2023  
AGENDA**

<b>12:45pm – 1:30pm</b>	<b>Lunch (45 min.)</b>
<b>1:30pm – 2:30pm</b>	<b>Open Public Hearing (60 min.)</b>
<b>2:30pm – 3:30pm</b>	<b>Committee Discussion, Recommendations, and Vote (60 Min)</b>
<b>3:30 pm</b>	<b>Adjourn the meeting- DFO</b>